

59. The composition of Claim 58, wherein the pH is 6.8 to 7.8.

60. The composition of Claim 27, wherein the fatty acid-acylated insulin is N-acylated Lys^{B29} human insulin.--

Remarks

I. Status Of The Claims

Claims 29, 31 and 33 have been amended. New claims 57-60 have been added. Claims 27-35 and 56-60 are active in this application.

II. Support For The Amendment

Alternative language has been used in amended claims 29, 31 and 33.

Support for new claim 57 is found in the specification at page 9, line 14 to page 10, line 10.

Support for new claim 58 is found in the specification at page 8, lines 8-10.

Support for new claim 59 is found in the specification at page 9, lines 19-20.

Support for new claim 60 is found in the specification at page 6, line 27.

No new matter has been added by this amendment.

BEST AVAILABLE COPY

III. The Rejection Under 35 U.S.C. 112, Second Paragraph


At page 2 of the Office Action, the Examiner rejected claims 29 and 31 under 35 U.S.C. 112, second paragraph, as allegedly indefinite. Applicants respectfully traverse this rejection. Claims 29 and 31 have been amended, and Applicants respectfully request that this rejection be withdrawn.

IV. The Rejections Under 35 U.S.C. 102(e)

At page 3 of the Office Action, the Examiner rejected claims 27-35 and 56 under 35 U.S.C. 102(e), as allegedly anticipated by either (a) U.S. Patent No. 5,750,497 (Havelund et al.), or (b) U.S. Patent No. 6,011,007 (Havelund et al.).

Applicants respectfully request that these rejections be held in abeyance until the claims are found otherwise allowable. In the meantime, Applicants will determine whether a request for interference will be filed.

Respectfully submitted,



Grant E. Reed
Attorney for Applicants
Registration No. 41,264
Phone: 317-276-1664

Eli Lilly and Company
Patent Division/GER
Lilly Corporate Center
Indianapolis, Indiana 46285

10/9/01

BEST AVAILABLE COPY

Version Of Amended Claims With Markings To Show Changes Made

29. (Once Amended) The composition of Claim 28, wherein the solution comprises [further comprising from] about 0.2 mole to about 0.7 mole of zinc per mole of fatty acid-acylated insulin.

30. (Once Amended) The composition of Claim 30, further comprising a phenolic compound at a concentration of from 0.5 mg to 5 mg [of] per milliliter of the aqueous solution.

33. (Once Amended) The composition of claim 32, wherein the fatty acid-acylated insulin is N-palmitoyl Lys^{B29} human insulin, and wherein the solution comprises [is comprised of] from about 0.3 mole to about 0.55 mg per milliliter of the aqueous solution.

BEST AVAILABLE COPY